AbCellera Biologics Inc. (ABCL)财务
NASDAQ · Healthcare · Biotechnology · 员工562人 · CEO Carl Hansen
- 股价
- $12.27 -6.19%
- 市值
- $39.8亿
- 企业价值
- $39.9亿
- 最近财报
- Q2 '26 2026-08-05提交
- 下次财报
- 2026-11-09
营收(TTM)$6620万+101.3% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)-340.3%+507.4 百分点 对比去年同期营业利润 -$2.25亿
净利润(TTM)-$1.65亿+0.6% 对比去年同期税后,含营业外收益
自由现金流(TTM)-$1.79亿-28.9% 对比去年同期资本支出 $2470万
稀释EPS(TTM)-$0.54+3.6% 对比去年同期最近4个季度之和
净现金$4.04亿-1.6% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $39.8亿 EV $39.9亿
- 营收
- $6620万 过去12个月
- 营收增速
- – 下一财年
- 净利润率
- -248.8% 净利润 / 营收,TTM
- P/E
- -22.7×
- P/S
- 60.1× 股价 / 营收,TTM
- EV / EBITDA
- -23.6× TTM
- 自由现金流
- -$1.79亿 过去12个月
- 净利润
- -$1.65亿 过去12个月
- 营收预期
- – 下一财年
- 盈利
- 2026-11-09
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-08-05):营收低于预期48.4%,EPS 低于预期9.8%营收$405万,预期$785万(-48.4%);EPS -$0.18,预期-$0.16(-9.8%)。
- 营收增长放缓:同比-76.3%Q2 '26营收$405万,此前四个季度的平均值为263.9%。
- 营业利润率-340.3%(TTM),较去年同期+507.4 百分点营收增长101.3%,营业利润增长19.2%。
- 资本支出占营收的37.4%(去年为177.1%)最近4个季度投入$2470万(同比-57.5%)。自由现金流-$1.79亿。
- 稀释股数一年内增加2.4%Q2 '26稀释股数3.06亿,一年前为2.99亿。
- 净现金 $4.04亿现金 + 短期投资 $5.4亿,含租赁债务 $1.36亿;一年前净现金 $4.11亿。
上一季度:Q2 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q2 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $405万 | $1710万 | -76.3% |
| 毛利率 | 100.0% | 100.0% | 0.0 百分点 |
| 营业利润 | -$6280万 | -$4960万 | -26.6% |
| 营业利润率 | -1,550.0% | -290.2% | -1,259.8 百分点 |
| 净利润 | -$5540万 | -$3470万 | -59.6% |
| 稀释EPS | -$0.18 | -$0.12 | -50.0% |
| 经营现金流 | -$3390万 | -$3240万 | -4.5% |
| 资本支出 | $213万 | $1340万 | -84.0% |
| 自由现金流 | -$3600万 | -$4580万 | +21.4% |
| R&D | $4600万 | $3920万 | +17.3% |
| 股权激励费用 | $1230万 | $1420万 | -13.5% |
实际 vs 一致预期
2026-08-05| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $405万 | $785万 | -48.4% |
| EPS(一致预期口径) | -$0.18 | -$0.16 | -9.8% |
来自2026-08-05发布的Q2 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| License | – | – | – | – | – | |
| Research Fees | $390万 | -41.2% | 96.3% | $2850万 | +4.8% | |
| Licensing and Royalty Revenue | $14.9万 | – | 3.7% | – | – |
利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- -$1.55亿
- 资本支出
- -$2470万
- 股票回购
- $0
- 股息
- $0
- 收购
- -$500万
- 债务净发行
- $2530万
- 股权激励费用
- $5110万
- 自由现金流
- -$1.79亿
- 股东回报 / FCF
- 0.0%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | -22.7× | 21.8× 5年中的2年 | 18.1× – 25.5× |
| EV / EBITDA | -23.6× | 12.3× 5年中的2年 | 9.9× – 14.7× |
| EV / 营收 | 60.3× | 19.4× | 5.3× – 42.0× |
| 股价 / FCF | -22.2× | 17.6× 5年中的2年 | 14.1× – 21.2× |
| 股价 / 净资产 | 4.2× | 1.9× | 0.8× – 3.8× |
| FCF收益率 | -4.5% | -6.9% | -21.7% – 7.1% |
| 投入资本回报率 | -15.0% | -5.2% | -19.9% – 11.9% |
| 净资产收益率 | -17.5% | -3.1% | -15.4% – 15.0% |
分析师
一致目标价 $16.33 (+33.1%)
区间 $7.00 – $30.00 · 评级 Buy
强烈买入0
买入11
持有1
卖出0
强烈卖出0
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
AbCellera Biologics Inc.在近期10-Q / 10-K文件中标记的全部173项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| Accounts Payable and Accrued Liabilities, Current | $1210万 | $3200万 | -62.2% | $2520万 | $3440万 | -26.6% |
| Accounts Payable and Other Accrued Liabilities, Current | $3250万 | $5010万 | -35.1% | $5080万 | $5500万 | -7.7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$315万 | -$266万 | -18.6% | -$423万 | -$438万 | +3.3% |
| Additional Paid in Capital, Common Stock | $2.06亿 | $1.81亿 | +13.5% | $1.98亿 | $1.66亿 | +19.2% |
| Amortization of Intangible Assets | $93.1万 | $92.9万 | +0.2% | $370万 | $1430万 | -74.1% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 7620万 | 7170万 | +6.2% | 7090万 | 5830万 | +21.8% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $1230万 | $1440万 | -14.7% | $5630万 | $6760万 | -16.7% |
| Assets | $13.1亿 | $14亿 | -6.7% | $13.6亿 | $13.6亿 | -0.3% |
| Assets, Current | $6.79亿 | $7.42亿 | -8.5% | $7.28亿 | $7.51亿 | -3.1% |
| Assets, Noncurrent | $6.28亿 | $6.6亿 | -4.8% | $6.29亿 | $6.09亿 | +3.2% |
| Business Combination, Contingent Consideration, Liability, Current | $02025-12-31 | $809万 | -100.0% | $0 | $809万 | -100.0% |
| Cash | $9930万2025-12-31 | $1.27亿 | -21.9% | $9930万 | $1.27亿 | -21.9% |
| Cash and Cash Equivalents, at Carrying Value | $1.2亿 | $9240万 | +29.9% | $1.29亿 | $1.56亿 | -17.8% |
| Cash and Cash Equivalents, at Carrying Value | 61,800,000 CAD2025-12-31 | 55,600,000 CAD | +11.2% | 61,800,000 CAD | 55,600,000 CAD | +11.2% |
| Cash Equivalents, at Carrying Value | $2930万2025-12-31 | $2920万 | +0.3% | $2930万 | $2920万 | +0.3% |
| Cash, Cash Equivalents, and Short-term Investments | $5.4亿 | $5.53亿 | -2.3% | $5.34亿 | $6.26亿 | -14.7% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1.45亿 | $1.17亿 | +23.5% | $1.54亿 | $1.81亿 | -15.3% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $1.47亿 | $1.2亿 | +22.8% | $1.55亿 | $1.84亿 | -15.4% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $4320万 | -$6680万 | +164.7% | -$2840万 | $2300万 | -223.3% |
| Common Stock, No Par Value | $0.00 | $0.00 | – | $0.00 | $0.00 | – |
| Common Stock, Par or Stated Value Per Share | $0.002025-12-31 | $0.00 | – | $0.00 | $0.00 | – |
| Common Stock, Shares, Issued | 3.06亿 | 2.96亿 | +3.6% | 3.01亿 | 2.96亿 | +1.6% |
| Common Stock, Shares, Outstanding | 3.06亿 | 2.96亿 | +3.6% | 3.01亿 | 2.96亿 | +1.6% |
| Common Stock, Value, Issued | $8.21亿 | $7.92亿 | +3.7% | $8.02亿 | $7.77亿 | +3.2% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$5620万 | -$3040万 | -84.8% | -$1.46亿 | -$1.66亿 | +11.6% |
| Contract with Customer, Liability | $6120万 | $2860万 | +114.0% | $1700万 | $1920万 | -11.4% |
| Contract with Customer, Liability, Current | $2070万 | $1690万 | +22.2% | $1350万 | $1350万 | 0.0% |
| Contract with Customer, Liability, Noncurrent | $4050万 | $1160万 | +247.7% | $570万2024-12-31 | $820万 | -30.4% |
| Contract with Customer, Liability, Revenue Recognized | $370万 | $410万 | -9.8% | $1180万 | $2060万 | -42.7% |
| Current Federal Tax Expense (Benefit) | – | – | – | -$3000万 | -$1850万 | -62.8% |
| Current Foreign Tax Expense (Benefit) | – | – | – | -$20.1万 | $67.1万 | -130.0% |
| Current Income Tax Expense (Benefit) | – | – | – | -$3020万 | -$1780万 | -70.0% |
| Debt Securities, Available-for-sale | $4.2亿 | $4.61亿 | -8.8% | $4.05亿 | $4.69亿 | -13.6% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $74.9万 | -100.0% |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | -$93.8万 | -$2050万 | +95.4% |
| Deferred Income Tax Liabilities, Net | $912万2025-12-31 | $1010万 | -9.3% | $912万 | $1010万 | -9.3% |
| Deferred Tax Assets, Gross | $1.35亿2025-12-31 | $1.04亿 | +30.2% | $1.35亿 | $1.04亿 | +30.2% |
| Deferred Tax Assets, Operating Loss Carryforwards | $213万2025-12-31 | $1560万 | -86.4% | $213万 | $1560万 | -86.4% |
| Deferred Tax Assets, Operating Loss Carryforwards, Foreign | $480万2025-12-31 | $1790万 | -73.2% | $480万 | $1790万 | -73.2% |
| Deferred Tax Assets, Other | $106万2025-12-31 | $539万 | -80.3% | $106万 | $539万 | -80.3% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $5600万2025-12-31 | $3360万 | +67.0% | $5600万 | $3360万 | +67.0% |
| Deferred Tax Assets, Valuation Allowance | $5620万2025-12-31 | $4990万 | +12.7% | $5620万 | $4990万 | +12.7% |
| Deferred Tax Liabilities, Gross | $8770万2025-12-31 | $6370万 | +37.7% | $8770万 | $6370万 | +37.7% |
| Deferred Tax Liabilities, Intangible Assets | $865万2025-12-31 | $959万 | -9.9% | $865万 | $959万 | -9.9% |
| Deferred Tax Liabilities, Net | $912万2025-12-31 | $1010万 | -9.3% | $912万 | $1010万 | -9.3% |
| Deferred Tax Liabilities, Other | $1170万2025-12-31 | $1750万 | -32.7% | $1170万 | $1750万 | -32.7% |
| Deferred Tax Liabilities, Property, Plant and Equipment | $3060万2025-12-31 | $2080万 | +47.2% | $3060万 | $2080万 | +47.2% |
| Depreciation | $610万 | $460万 | +32.6% | $1840万 | $1250万 | +47.1% |
| Depreciation, Depletion and Amortization | $699万 | $547万 | +27.8% | – | – | – |
| Depreciation, Depletion and Amortization, Nonproduction | $525万2025-09-30 | $3690万 | -85.8% | $2440万2023-12-31 | $2780万 | -12.4% |
| Dividends | – | – | – | $0 | $0 | – |
| Dividends, Cash | – | – | – | $0 | $0 | – |
| Earnings Per Share, Basic | -$0.18 | -$0.12 | -50.0% | -$0.49 | -$0.55 | +10.9% |
| Earnings Per Share, Diluted | -$0.18 | -$0.12 | -50.0% | -$0.49 | -$0.55 | +10.9% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | -$43万 | $76.1万 | -156.5% | $110万 | -$262万 | +141.9% |
| Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | – | – | – | -$5410万2024-12-31 | -$4700万 | -15.2% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | – | – | – | 27.0%2024-12-31 | 27.0% | 0.0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | – | – | – | $1230万 | $1520万 | -19.0% |
| Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | – | – | – | -6.9% | – | – |
| Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | – | – | – | $1190万 | – | – |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
数据截至 2026-11-02